AUG 26·SEC EDGARLow
Ye Xiaofeng sold $165K of ANL
Ye Xiaofeng (CFO) sold 11,667 shares of Adlai Nortye Group Ltd. (ANL) at an average of $14.11 ($13.98–$14.25, $0.16M total) across 2 trades over 2026-08-24 to 2026-08-26.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ANL
Adlai Nortye Ltd.
Price · $ANLvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ANL in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $165K 2 txs
Ye Xiaofeng2× · $165K
10b5-1 share of filings0%
Top stories · $ANLMore →
AUG 14·finanznachrichten.de
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Adlai Nortye Ltd. (NASDAQ: ANL) reported unaudited first-half 2026 results and pipeline updates. It said enrollment is ongoing for Phase I AN9025 in QD and QW arms, and it received Australia HREC approval for Phase I AN4035. Cash and short-term investments were $231.9M at June 30, 2026. Net loss fell to $5.3M; revenue rose to $13.1M.
JUL 16·rttnews.com
Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data
Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
ANL sentiment & insider activity
Recent ANL coverage spans financial news, market movers and insider activity.
In the last 30 days, ANL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($165K). The most active reporter was Ye Xiaofeng, CFO, with 2 filings.
What's driving ANL
Minor dilution of insider ownership; unlikely to move price materially.
Fresh cash runway and multiple near-term clinical milestones (AN9025 dosing, AN4035 first-patient timing) can re-rate risk for a clinical-stage biotech.
Insider ownership disclosure can provide a modest sentiment tailwind, but it is not an operational catalyst.
Board expansion is a positive scientific-validation signal but does not disclose new clinical data, trial starts, or financial guidance.
This reads more like a catalyst calendar than a new data print; upside is tied to future trial milestones.
alphai scores every news story that mentions ANL with an AI model for sentiment and relevance, and aggregates insider trades from Adlai Nortye Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ANL
Score
Ye Xiaofeng sold $165K of ANL
Ye Xiaofeng (CFO) sold 11,667 shares of Adlai Nortye Group Ltd. (ANL) at an average of $14.11 ($13.98–$14.25, $0.16M total) across 2 trades over 2026-08-24 to 2026-08-26.
1 min readAdlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Adlai Nortye Ltd. (NASDAQ: ANL) reported unaudited first-half 2026 results and pipeline updates. It said enrollment is ongoing for Phase I AN9025 in QD and QW arms, and it received Australia HREC approval for Phase I AN4035. Cash and short-term investments were $231.9M at June 30, 2026. Net loss fell to $5.3M; revenue rose to $13.1M.
6 min readTop Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data
Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readAdlai Nortye Ltd.: Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Adlai Nortye Ltd. (NASDAQ: ANL) said it expanded its Scientific Advisory Board by appointing Dr. David S. Hong and Dr. Piro Lito. The company links the SAB to guidance for its oncology pipeline, including RAS inhibitor programs AN9025 and AN4035, and immuno-oncology candidate AN8025.
3 min readTop Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update
Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
6 min read
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives $24.25 Consensus Price Target from Brokerages
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) has a consensus “Moderate Buy” rating from six covering analysts, MarketBeat reports: one sell and five buy. The average 1-year target price is $24.25. Analysts cited include HC Wainwright ($20), JonesTrading ($22), Cantor Fitzgerald (overweight), Oppenheimer ($32). ANL opened at $10.00 Monday.
3 min readAdlai Nortye to Participate in Upcoming Investor Conferences
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of ...
2 min readAdlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
2 min read
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Adlai Nortye (NASDAQ:ANL)
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ:ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
3 min readAdlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Adlai Nortye (NASDAQ:ANL)
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ:ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...
2 min read